Icosavax is turning its virus-like particle (VLP) technology to fight COVID-19. The news accompanies $16.5 million in new funding from

Via NIH.gov   A novel experimental vaccine against respiratory syncytial virus (RSV), a leading cause of severe respiratory illness in

BioSpace reporter Gail Dutton reports on Icosavax’s computationally designed virus-like particle (VLP) vaccine platform as a potential first-in-class vaccine for

For Nature Biotechnology’s annual survey, the list of companies represents some of the best science that was spun out from

Via UW Medicine   A first-of-its-kind nanoparticle vaccine candidate for respiratory syncytial virus has been designed in an international research